Search
Atazanavir
go.drugbank.com/drugs/DB01072ApprovedInvestigationalAtazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol … and other fatty substances in the blood).
Categories: Antivirals used in combination for the treatment of HIV infections, Amino Acids, Peptides, and ProteinsProducts: VIRAZAN 300MG, REYATAZ CAPSULE 300MGNeurological Manifestations
go.drugbank.com/conditions/DBCOND0031286Synonyms: Neurologic Signs and Symptoms, Neurological signs and symptoms NECPadeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigational[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799] … Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies.
Categories: Sensitizers Used in Photodynamic/radiation Therapy, Amino Acids, Peptides, and ProteinsMeprobamate
go.drugbank.com/drugs/DB00371ApprovedIllicitIt is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. … A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation.
Categories: Hypnotics and SedativesProducts: Meditran 400mg, Novo-mepro 400mgMethscopolamine
go.drugbank.com/drugs/DB11315ApprovedThe oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications. … Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors.
Mixtures: Allergy DN II, Allergy DN IICategories: Alimentary Tract and Metabolism, Mydriatics and CycloplegicsCeftobiprole medocaril
go.drugbank.com/drugs/DB14733Approvedfor skin and skin structure infections and bacteremia in April 2024. … [L50467] It received its first approval in Canada in October 2017 for use in certain patients with bacterial pneumonia,[L50472] and was subsequently approved in the United States with additional indications
Products: Zevtera 500 mg Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMecamylamine
go.drugbank.com/drugs/DB00657ApprovedInvestigationalMecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. … A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier.
Categories: Secondary and Tertiary AminesZanidatamab
go.drugbank.com/drugs/DB15471ApprovedInvestigational[A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903] … [A264718] It has been investigated for the treatment of HER2-positive solid tumors, including gastroesophageal, colorectal, and biliary tract cancers.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsPalopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA. … [A264199] Upon administration, PTH is cleaved from palopegteriparatide in a controlled manner to achieve a continuous systemic exposure of active PTH.
Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34, Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleCategories: Sex Hormones and Insulins, Amino Acids, Peptides, and ProteinsLandiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigational[A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November … [A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity